dehydroepiandrosterone has been researched along with abiraterone acetate in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sharifi, N | 1 |
| Auchus, RJ; Chang, KH; Evaul, K; Li, R; Liu, J; Sharifi, N; Sharma, KK; Yoshimoto, J | 1 |
| Audenet, F; Murez, T; Neuzillet, Y; Ripert, T; Villers, A | 1 |
| Araujo, JC; Efstathiou, E; Gyftaki, R; Li-Ning-Tapia, EM; Logothetis, CJ; Lu, JF; Maity, SN; Ramachandran, S; Titus, MA; Wu, G | 1 |
| Hillman, DW; Kohli, M; Liu, D; Niu, N; Qin, S; Vedell, PT; Wang, L; Weinshilboum, RM; Yu, J | 1 |
| Hamid, ARAH; Mochtar, CA; Schalken, JA; Sesari, SS; Tendi, W; Umbas, R; Verhaegh, G | 1 |
3 review(s) available for dehydroepiandrosterone and abiraterone acetate
| Article | Year |
|---|---|
Clinical implications of the 5α-androstanedione pathway for castration-resistant prostate cancer.
Topics: 3-Hydroxysteroid Dehydrogenases; Abiraterone Acetate; Androstadienes; Androstenediol; Antineoplastic Agents; Dehydroepiandrosterone; Etiocholanolone; Humans; Male; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Testosterone | 2011 |
[CYP17A1 inhibitors in prostate cancer: mechanisms of action independent of the androgenic pathway].
Topics: Abiraterone Acetate; Adjuvants, Immunologic; Androgens; Androstadienes; Androstenedione; Antineoplastic Agents; Dehydroepiandrosterone; Disease Progression; Humans; Male; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Treatment Outcome | 2013 |
The importance of targeting intracrinology in prostate cancer management.
Topics: Abiraterone Acetate; Androgen Antagonists; Androgens; Antineoplastic Agents; Benzamides; Dehydroepiandrosterone; Dihydrotestosterone; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Testosterone | 2019 |
3 other study(ies) available for dehydroepiandrosterone and abiraterone acetate
| Article | Year |
|---|---|
Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer.
Topics: 3-Hydroxysteroid Dehydrogenases; Abiraterone Acetate; Active Transport, Cell Nucleus; Androstadienes; Androstenedione; Animals; Antineoplastic Agents; Cell Line, Tumor; Dehydroepiandrosterone; Dihydrotestosterone; Drug Resistance, Neoplasm; Humans; Isoenzymes; Male; Mice; Mice, Inbred NOD; Mice, SCID; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Testosterone; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Androgens; Animals; Biopsy; Cell Line, Tumor; Dehydroepiandrosterone; Humans; Hydrocortisone; Male; Mass Spectrometry; Mice; Mice, SCID; Naphthalenes; Neoplasm Transplantation; Precision Medicine; Prednisone; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction; Steroid 17-alpha-Hydroxylase; Triazoles | 2016 |
TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Cell Cycle Proteins; Cell Proliferation; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dehydroepiandrosterone; DNA-Binding Proteins; Gene Expression Regulation; Gene Knockdown Techniques; Hep G2 Cells; Humans; Male; Neoplasm Metastasis; Nuclear Proteins; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; RNA, Messenger; Steroid 17-alpha-Hydroxylase; Treatment Outcome | 2018 |